A report about the HCV patients in Italy published by Cittadinanza Attivia and EpaC (two of the main HCV patients associations) shows that Italian Regions are significantly different in terms of structures and treatments for these kind of patients. The introduction of new therapies increased these differences in terms of access to new drugs. The number of centers that can administer these new therapies is not equally distributed among the Italian Regions. In Italy only 15% of HCV patients are eligible for new treatments and among these patients, only one out of four is actually treated. 
OBjECTIVES
The aim of this study is to give an overview of the treatments available for the patients with Hepatitis C Virus (HCV) through the segmentation of HCV patients in Italy.
METHODS
The study was carried out in 9 hepatology centers, treating HCV patients in 9 Italian Regions. The structures selected constitute a representative sample of the Italian scenario, being Centers of Excellence in HCV management in northern, southern, and center of Italy (representing about 24% of the 2.000 2 patients treated with first generation Triple Therapy in Italy). The centers examined treat about 9.122 patients, 786 of whom transplanted (Table 2 ). In 2013 they treated about 851 patients, 378 with double therapy and 473 with triple therapy. The patients' distribution has been investigated in terms of fibrosis stage (F0 to F4), therapy type (Triple, or Double therapy) and treatment status (naive or experienced patients). Some centers, like the one in Napoli and Udine, provided only information about patients treated in 2013 and not about the total number of HCV patients treated in the center.
RESULTS
Data (collected from structures and Workshop of Pharmacoeconomics in Hepatology) show that HCV patients are more concentrated in the two fibrosis stage extremes: 43% in F0-F1 Range, 23% in F2, 32% in F3-F4 Range and 2% unclassified (Table 2 - Figure 1 ). In some Regions there were also patients not classified (e.g. in Puglia there were 95 patients out of 572 not classified). On the contrary, at Regional level many differences were found in all of the three parameters examined. In the structure investigated in Campania, for example, 72% of patients receive TT and 76% are experienced, while in Lazio 72% of patients receive DT and 72% are naive. Furthermore, considering the fibrosis stage, the 46% of patients treated in a center operating in Bari is in the range F3-F4, whilst in the center in Milan the 56% of the HCV patients treated is in range F0-F1 (Table 3 
CONCLUSIONS
The study demonstrates that, concerning the treatment of HCV, there are significant differences among the hepatology centers, both in terms of patients' health status and therapy pathways. Common guideline, at national level, about the therapies and patients management could help the Regions and the prescribing centers in dealing with this pathology and its problems.
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